Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Fibrosis in Liver Transplant Recipients With Recurrent Hepatitis C
NCT00582738Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2007
- Primary completion
- Jan 2010
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in hepatitis C (HCV) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Fibrosis Staging Score (Measured by the Ishak-Knodell Staging Score) at 24 months. Started Dec 2007; status: terminated.
02
Drugs
everolimus
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00582738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582738.